Association between inflammation,body mass index,and long-term outcomes in patients after percutaneous coronary intervention:A large cohort study  

作　　者：Guyu Zeng Deshan Yuan Sida Jia Peizhi Wang Liu Ru Tianyu Li Ce Zhang Xueyan Zhao Song Lei Lijian Gao Jue Chen Yuejin Yang Shubin Qiao Runlin Gao Xu Bo Jinqing Yuan 

机构地区：[1]National Clinical Research Center for Cardiovascular Diseases,State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China [2]Department of Cardiology,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China

出　　处：《Chinese Medical Journal》2023年第14期1738-1740,共3页中华医学杂志（英文版）

基　　金：supported by grants from the National Clinical Research Center for Cardiovascular Diseases,Fuwai Hospital,Chinese Academy of Medical Sciences(No.NCRC2020013);CAMS Innovation Fund for Medical Sciences(No.2020-12M-C&T-B-049).

摘　　要：To the Editor:Despite optimal secondary prevention treatments,a large proportion of patients with coronary artery disease(CAD)after percutaneous coronary intervention(PCI)are still at a high risk of recurrent cardiovascular events.Inflammation is a well-known component of residual cardiovascular risk and contributes to progression of atherosclerosis,leading to destabilization and rupture of atheroma plaques.^([1])As a downstream protein in the activated inflammatory pathway that mediates the progression of atherosclerosis,high-sensitivity C-reactive protein(hsCRP)is widely used as a biomarker of inflammatory status and predictor of adverse outcomes in the settings of primary and secondary prevention of cardiovascular disease.

关 键 词：PREVENTION CORONARY PATIENTS 

分 类 号：R541.4[医药卫生—心血管疾病]